Use of Sodium‐Glucose Transport Protein 2 Inhibitors and the Incidence of Urolithiasis: A Multi‐Database and Cross‐Country Study in Patients With Type 2 Diabetes Mellitus
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3626 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Mu-Chi Chung und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Urolithiasis, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: China Medical University, Taichung Veterans General Hospital.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The benefits of sodium‐glucose transport protein 2 inhibitor (SGLT2i) use on severe urolithiasis requiring surgery remains unclear. All patients with incident T2D in Taiwan National Health Institution databases (2016–2021) and TriNetX datasets (2014–2023) were retrospectively analyzed. The study analyzed a propensity score‐matched pairs with T2D treated with SGLT2i or dipeptidyl peptidase 4 inhibitors (DPP4i). The primary outcome was the incidence of urolithiasis and urolithiasis requiring surgery during the study period. Urolithiasis diagnoses were identified using International Classification of Diseases diagnostic codes and categorized into upper and lower urinary tract stones. Cases of urolithiasis requiring surgery were determined by the presence of both diagnostic codes and surgical procedure codes within the same outpatient visit or hospitalization. Conditional and time‐dependent Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). During the study period, 5700 participants were diagnosed with urolithiasis, 1297 participants were urolithiasis requiring surgery in Taiwan NHIRD cohort 8438 participants with urolithiasis as well as 289 participants with urolithiasis requiring surgery were in the TriNetX cohort. Adjusted HRs of urolithiasis and urolithiasis requiring surgery were 0.82‐fold (95% CI, 0.77–0.87), 0.72‐fold (95% CI, 0.63–0.82) in Taiwan NHIRD, 0.84 (95% CI, 0.78–0.90), and 0.62 (95% CI, 0.44–0.88) in TriNetX cohort respectively. Similar protective associations with SGLT2i use against urolithiasis were observed across subgroups in both datasets from Taiwan NHIRD and TriNetX. In conclusion, SGLT2i might protect against kidney stones and severe cases requiring surgery in T2D patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
- Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
- Division of Clinical Toxicology, Departmentof Medical Toxicology, Taichung Veterans General Hospital, Taichung, Taiwan.
- Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
- Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan.
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
ORCID-Profile: Mu-Chi Chung, Chia-Yen Lin, Chao-Hsiang Chang, Yi-Huei Chang, Po-Jen Hsiao, Chi-Shun Lien, Laing-You Wu, Ming-Ju Wu, Jeng-Jer Shieh, Peir-Haur Hung, Hsin-Hua Chen, Chi-Jung Chung
Förderung
- China Medical University
- Taichung Veterans General Hospital
Zitieren
APA
Chung, M. C., Lin, C. Y., Chang, C. H., Chang, Y. H., Hsiao, P. J., Lien, C. S., Wu, L. Y., Wu, M. J., Shieh, J. J., Hung, P. H., Chen, H. H., & Chung, C. J. (2025). Use of Sodium‐Glucose Transport Protein 2 Inhibitors and the Incidence of Urolithiasis: A Multi‐Database and Cross‐Country Study in Patients With Type 2 Diabetes Mellitus. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3626
Vancouver
Chung MC, Lin CY, Chang CH, Chang YH, Hsiao PJ, Lien CS, et al. Use of Sodium‐Glucose Transport Protein 2 Inhibitors and the Incidence of Urolithiasis: A Multi‐Database and Cross‐Country Study in Patients With Type 2 Diabetes Mellitus. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3626
BibTeX
@article{Chung2025,
author = {Chung, Mu-Chi and Lin, Chia-Yen and Chang, Chao-Hsiang and Chang, Yi-Huei and Hsiao, Po-Jen and Lien, Chi-Shun and Wu, Laing-You and Wu, Ming-Ju and Shieh, Jeng-Jer and Hung, Peir-Haur and Chen, Hsin-Hua and Chung, Chi-Jung},
title = {Use of Sodium‐Glucose Transport Protein 2 Inhibitors and the Incidence of Urolithiasis: A Multi‐Database and Cross‐Country Study in Patients With Type 2 Diabetes Mellitus},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3626}
}
EUVIMED